Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17148520 | 0.83 | KMT2A (0.39) | MAPK1KMT2AMEN1ALDH1A1RXFP1 | |
| SCHEMBL27374794 | 0.77 | MAPK1 (0.41) | MAPK1KMT2AMEN1GAA | |
| SCHEMBL2421365 | 0.74 | KMT2A (0.51) | MAPK1KMT2AMEN1ALDH1A1RXFP1 | |
| SCHEMBL2750787 | 0.73 | KMT2A (0.43) | MAPK1KMT2AMEN1ALDH1A1RXFP1 | |
| SCHEMBL9195960 | 0.73 | CA5A (0.40) | MAPK1KMT2AMEN1ALDH1A1RXFP1 | |
| SCHEMBL12763742 | 0.72 | HCAR2 (0.43) | KMT2AALDH1A1NAPRTTTRTSHR | |
| SCHEMBL3774595 | 0.72 | MAPK1 (0.69) | MAPK1KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL9192048 | 0.72 | CYP2D6 (0.45) | MAPK1KMT2AMEN1ALDH1A1RXFP1 | |
| SCHEMBL16505140 | 0.71 | ALDH1A1 (0.43) | MAPK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL27956182 | 0.70 | AGBL2 (0.45) | MAPK1KMT2AMEN1ALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178558-B2 | Substituted pyridylmethyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2069302-B1 | SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090318497-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER, INC. | 2009-12-24 | — | — | US | disclosed |
| EP-2069302-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | Pfizer Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008032204-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318497-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS | CNR1, CNR2, HCAR3 | MAPK1 1218/4885KMT2A 2933/4885MEN1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.